Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C86H116N16O12S4 |
Molecular Weight | 1694.201 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@@H](CSCC(=O)NCCCC[C@@H](NC(=O)CSC[C@H]5CN(CCC)[C@]6([H])CC7=CNC8=C7C(=CC=C8)[C@@]6([H])C5)C(=O)N[C@H]9CSSC[C@H](NC(=O)[C@H](CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC%10=CNC%11=C%10C=CC=C%11)NC(=O)[C@H](CC%12=CC=C(O)C=C%12)NC9=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CN2CCC
InChI
InChIKey=WLBJBODHTIKYSL-JFPOTJHNSA-N
InChI=1S/C86H116N16O12S4/c1-5-30-101-41-51(32-60-58-17-14-22-64-76(58)54(39-91-64)36-72(60)101)43-115-47-74(105)89-29-13-11-21-66(93-75(106)48-116-44-52-33-61-59-18-15-23-65-77(59)55(40-92-65)37-73(61)102(42-52)31-6-2)81(109)99-70-45-117-118-46-71(86(114)100-78(49(4)103)79(88)107)98-80(108)62(7-3)94-82(110)67(20-10-12-28-87)95-84(112)69(35-53-38-90-63-19-9-8-16-57(53)63)97-83(111)68(96-85(70)113)34-50-24-26-56(104)27-25-50/h8-9,14-19,22-27,38-40,49,51-52,60-62,66-73,78,90-92,103-104H,5-7,10-13,20-21,28-37,41-48,87H2,1-4H3,(H2,88,107)(H,89,105)(H,93,106)(H,94,110)(H,95,112)(H,96,113)(H,97,111)(H,98,108)(H,99,109)(H,100,114)/t49-,51-,52-,60-,61-,62+,66-,67+,68+,69-,70+,71+,72-,73-,78+/m1/s1
Molecular Formula | C86H116N16O12S4 |
Molecular Weight | 1694.201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:35:14 GMT 2023
by
admin
on
Sat Dec 16 18:35:14 GMT 2023
|
Record UNII |
L32IM11DV4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11439
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | INN | ||
|
778630-77-6
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | |||
|
868562-36-1
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | |||
|
L32IM11DV4
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | |||
|
154584814
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | |||
|
C88345
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY | |||
|
300000007841
Created by
admin on Sat Dec 16 18:35:14 GMT 2023 , Edited by admin on Sat Dec 16 18:35:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antineoplastic; Mechanism of Action: Dopamine receptor agonist, Somatostatin receptor agonist; Highest Development Phases: Discontinued for Acromegaly, Malignant carcinoid syndrome, Neuroendocrine tumours, Pituitary cancer; Most Recent Events: 16 Dec 2010 Discontinued - Preclinical for Pituitary cancer in France (SC), 16 Dec 2010 Discontinued - Preclinical for Neuroendocrine tumours in France (SC), 16 Dec 2010 Discontinued - Phase-II for Carcinoid syndrome in Europe (SC)
|